Bavarian Nordic receives special designation from FDA

The US Food and Drug Administration has awarded the so-called Breakthrough Therapy Designation to Bavarian Nordic’s vaccine candidate for RSV prevention in adults aged 60 years or older.

Photo: Philip Davali/Ekstra Bladet, Philip Davali

Danish Bavarian Nordic has received a particularly sought-after special regulatory status from the US Food and Drug Administration (FDA), the company announces in a press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs